Lancet Regional Health-Europe最新文献

{"title":"Nasogastric tube after oesophagectomy and risk of anastomotic leak: a Nordic, multicentre, open-label, randomised, controlled, non-inferiority trial","authors":"Jakob Hedberg ,&nbsp;Joonas Kauppila ,&nbsp;Eirik Kjus Aahlin ,&nbsp;David Edholm ,&nbsp;Gjermund Johnsen ,&nbsp;Jan Johansson ,&nbsp;Pernilla Lagergren ,&nbsp;Mats Lindblad ,&nbsp;Fredrik Lindberg ,&nbsp;Olli Helminen ,&nbsp;Per Löfdahl ,&nbsp;Dag Tidemann Førland ,&nbsp;Mads Vikhammer ,&nbsp;Pieter de Heer ,&nbsp;Magnus Sundbom ,&nbsp;Eva Szabo ,&nbsp;Oscar Åkesson ,&nbsp;Magnus Nilsson ,&nbsp;Albert Nilsson ,&nbsp;Michael Achiam ,&nbsp;Tom Mala","doi":"10.1016/j.lanepe.2025.101411","DOIUrl":"10.1016/j.lanepe.2025.101411","url":null,"abstract":"<div><h3>Background</h3><div>Oesophagectomy, a corner stone in curative treatment of oesophageal cancer, is a complex procedure with high complication rates. Postoperative gastric tube decompression is debated and some centres are abandoning routine nasogastric (NG) tube use. We hypothesised that postoperative NG tube removal is non-inferior to five days of NG tube decompression, with regard to the risk of anastomotic leak.</div></div><div><h3>Methods</h3><div>In this open-label, non-inferiority randomised controlled trial across 12 hospitals in Sweden, Norway, Denmark and Finland, participants treated for oesophageal or gastroesophageal junctional cancer with oesophagectomy were randomly assigned (1:1) to no postoperative NG tube or five days of NG tube decompression. Anastomotic leak was the primary outcome and secondary outcomes included pneumonia and length of hospital stay. Analyses were performed on the intention to treat and per protocol populations and non-inferiority for anastomotic leak was defined as a risk difference below 9%. <span><span>ISRCTN.com</span><svg><path></path></svg></span> registration ISRCTN39935085.</div></div><div><h3>Findings</h3><div>Between January 1st 2022 and March 27th 2024, 448 patients were randomly assigned, 217 to no postoperative NG tube and 231 to five days NG tube treatment. The mean age was 67.5 (standard deviation (SD) 9.8) years and 367 (81.9%) were males. Non-inferiority with regard to anastomotic leak for no NG tube decompression could not be shown with 48 patients (22.1% (95% confidence interval (CI) 16.8%, 28.2%)) having anastomotic leak compared to 35 (15.2% (95% CI 10.8%, 20.4%)) with five days of NG tube decompression, a risk difference of −7.0% (95% CI −14.4%, 0.00%), p_{non-inferiority} 0.30. In a <span><span>Supplementary analysis</span></span>, patients had a lower risk of anastomotic leak if postoperative NG decompression was used. Rate of other complications, e.g., pneumonia, were similar between groups. In a per-protocol analysis, the risk difference was −11.3% to the advantage of NG tube (95% CI, −19.1, −0.3%).</div></div><div><h3>Interpretation</h3><div>We could not establish safety (increased risk of anastomotic leak) and therefore do not support omission of NG tube after oesophagectomy.</div></div><div><h3>Funding</h3><div>This trial was funded by the <span>Swedish Cancer Society</span> and the <span>Nordic Cancer Union</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"57 ","pages":"Article 101411"},"PeriodicalIF":13.0,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144738159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical presentation, management and outcome of 11,132 patients with liposarcoma patients: a population-based study from the NETSARC+ registry","authors":"Jean-Yves Blay ,&nbsp;Maud Toulmonde ,&nbsp;Thibaud Valentin ,&nbsp;Nelly Firmin ,&nbsp;Sarah Watson ,&nbsp;Florence Duffaud ,&nbsp;Emmanuelle Bompas ,&nbsp;Maria Rios ,&nbsp;Mikael Ropars ,&nbsp;Philippe Anract ,&nbsp;Armelle Dufresne ,&nbsp;Justine Gantzer ,&nbsp;Louis-Romée Le Nail ,&nbsp;Esma Saada ,&nbsp;Alice Hervieu ,&nbsp;Francois Bertucci ,&nbsp;Pascale Dubray-Longeras ,&nbsp;Vincent Crenn ,&nbsp;Christophe Perrin ,&nbsp;Pauline Soibinet ,&nbsp;Axel Le Cesne","doi":"10.1016/j.lanepe.2025.101403","DOIUrl":"10.1016/j.lanepe.2025.101403","url":null,"abstract":"<div><h3>Background</h3><div>Liposarcomas (LPS) are among the most common sarcomas, but gather a diversity of rare to ultrarare molecular subtypes whose presentations and natural histories are partially characterized. The aim of the work was to describe the presentation and outcome of the different LPS histotypes from the NETSARC+ registry.</div></div><div><h3>Methods</h3><div>NETSARC+ (<span><span>netsarc.org</span><svg><path></path></svg></span>) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDTB), funded by the French INCA since 2010 aiming to improve the quality of care of sarcoma patients. Patients’ characteristics, treatment and outcomes are collected in a nationwide database. This work describes the outcome of all LPS confirmed by central review pathology review and integrated between 2010 and 2023 in the NETSARC+ database.</div></div><div><h3>Findings</h3><div>11,132 liposarcomas are included in the database for an estimated incidence of 11.5/10⁶/y. Median age was 65 (Q1–Q3: 53–74, range 0–97 y), with 6529 males (58.7%), with 4220 (37.9%) dedifferentiated (DDLPS), 1838 (16.5%) well differentiated LPS (WDLPS) &amp; 2424 (21.8%) atypical lipomatous tumours (ALT), 1371 (12.3%) myxoid LPS (MyxLPS), 450 (4.0%) pleomorphic LPS (PLPS), 177 (1.6%) high grade myxoid LPS (HGMLPS), 24 (0.2%) mixed type liposarcomas (MTLPS), 14 (0.1%) myxoid pleomorphic LPS (MPLPS) and 614 (5.5%) non classified LPS (NCLPS). Age, sex and sites differed across histotypes, but overall, all histotypes were represent in all age groups and sites. We report first on a difference in the sex ratio of liposarcoma in different age groups. Women were less frequently affected with liposarcomas after 50, in DDLPS, MyxLPS and HGMLPS. The median overall survival of DDLPS was 144 months, significantly worse than that of MyxLPS (HR: 0.26 [95% CI 0.21–0.33]), PLPS (HR: 0.76 [95% CI 0.59–0.98]), HGMLPS (HR: 0.30 [95% CI 0.18–0.50]), WDLPS (HR: 0.30 [95% CI 0.24–0.37]), unclassified LPS (HR: 0.53 [95% CI 0.37–0.75]). In addition to a lower incidence, women aged &gt;50 had a better relapse free and overall survival than male, while this was not observed in the group aged 50 or under. In multivariate analyses, size and age were independent prognostic factors for the most common subgroups, but specific prognostic parameters were observed in each molecular subgroup. Female &gt;50 was an independent favorable prognostic factor for the largest groups of DDLPS.</div></div><div><h3>Interpretation</h3><div>In this nationwide series of pathology-confirmed LPS, the clinical presentation, management and survival of histotypes are very different with age-related sex differences favoring women &gt;50. DDLPS is the subtype with the worse prognosis.</div></div><div><h3>Funding</h3><div>This work was supported by the following grants: <span>NetSARC+</span> (INCA), <span>RREPS</span> (INCA), <span>RESOS</span> (INCA), <span>INTERSARC+</span> (INCA","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"57 ","pages":"Article 101403"},"PeriodicalIF":13.0,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144738160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association","authors":"Manon Allaire ,&nbsp;Leonardo G. Da Fonseca ,&nbsp;Marco Sanduzzi-Zamparelli ,&nbsp;Won-Mook Choi ,&nbsp;Cecilia Monge ,&nbsp;Ken Liu ,&nbsp;Michael Leibfried ,&nbsp;Sarah Manes ,&nbsp;Zorana Maravic ,&nbsp;Milan Mishkovikj ,&nbsp;Jordi Bruix ,&nbsp;Helen L. Reeves ,&nbsp;Riad Salem ,&nbsp;Bruno Sangro","doi":"10.1016/j.lanepe.2025.101408","DOIUrl":"10.1016/j.lanepe.2025.101408","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) is a major cause of cancer deaths worldwide. It is often diagnosed at advanced stages, requiring systemic therapies like sorafenib, lenvatinib, atezolizumab-bevacizumab, and tremelimumab-durvalumab. However, disparities in access to systemic therapies for HCC remain a major global challenge, particularly in low- and middle-income countries where high drug costs, regulatory delays, and limited healthcare infrastructure impede treatment. Drawing on international experience, we highlight the urgent need for coordinated advocacy and innovative programs—such as Project Orbis and expedited approval pathways—to improve drug availability. Multisectoral collaboration among patient groups, clinicians, policymakers, and industry is essential to ensure equitable access to life-saving therapies and to reduce the burden of HCC worldwide.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"57 ","pages":"Article 101408"},"PeriodicalIF":13.0,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144738161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cause-specific mortality in individuals with and without mental disorders according to socioeconomic position: a population-based cohort study","authors":"Danni Chen ,&nbsp;Linda Ejlskov ,&nbsp;Julie Werenberg Dreier ,&nbsp;Natalie C. Momen ,&nbsp;Lisbeth Mølgaard Laustsen ,&nbsp;Henrik Toft Sørensen ,&nbsp;Jayati Das-Munshi ,&nbsp;Oleguer Plana-Ripoll","doi":"10.1016/j.lanepe.2025.101397","DOIUrl":"10.1016/j.lanepe.2025.101397","url":null,"abstract":"<div><h3>Background</h3><div>Mental disorders are associated with elevated cause-specific mortality rates; however, the role of socioeconomic position (SEP) on these associations remains unclear. We aimed to examine cause-specific mortality associated with diverse mental disorders by SEP, on both relative and absolute scales.</div></div><div><h3>Methods</h3><div>This cohort study included all residents of Denmark on January 1, 2000, and followed them until December 31, 2020. Information on mental disorders, SEP (income percentile, further categorized into low [&lt;20%], middle [20–79%], and high [≥80%]), and cause-specific mortality was obtained from nationwide registers. We estimated mortality rate ratios (MRRs) and rate differences (MRDs) with Poisson regression models.</div></div><div><h3>Findings</h3><div>Overall, 5,316,626 individuals (50.6% females, median age 38.3 years) were followed up to 21 years. People with mental disorders (versus without) experienced higher mortality rates from all 11 specific causes of death, regardless of SEP. MRDs (per 10,000 person-years) between people with versus without mental disorders were greater in the lower than the higher SEP groups for all 11 causes of death, except suicide where MRDs were largest in the high-SEP group (9.3 [95% CI 8.6–9.9] versus 7.2 [7.0–7.5] in middle- and 6.1 [5.8–6.4] in low-SEP groups). MRRs were similar across SEP groups for most causes, with a 30–40% increase for cancer-related deaths, and more than two-fold increase for other cause-specific deaths. Conversely, relative risks of dying from alcohol misuse and suicide were higher among the high-SEP groups (MRRs: 10.9 [95% CI 9.9–12.0] and 17.7 [16.0–19.6] respectively) than the middle-SEP (8.3 [8.0–8.6] and 11.1 [10.6–11.7]) or low-SEP (4.8 [4.6–5.0] and 7.9 [7.3–8.6]) groups. All subgroup, sensitivity, and post-hoc analyses indicated similar patterns.</div></div><div><h3>Interpretation</h3><div>We provide detailed descriptions of cause-specific mortality associated with specific mental disorders by SEP and reveal potentially differential roles of SEP across causes of death.</div></div><div><h3>Funding</h3><div><span>Independent Research Fund Denmark</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"56 ","pages":"Article 101397"},"PeriodicalIF":13.0,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Halifax Declaration: protecting health, dignity, and human rights in an era of forced displacement","authors":"Gabriel E. Fabreau ,&nbsp;Annalee Coakley ,&nbsp;Sarah K. Clarke ,&nbsp;Nesma El-Shazly ,&nbsp;Apostolos Veizis ,&nbsp;Joanne Liu ,&nbsp;Patrick Bodenmann ,&nbsp;William M. Stauffer ,&nbsp;Anisa Ibrahim ,&nbsp;Nathan S. Bertelsen ,&nbsp;Allen Keller ,&nbsp;Karl Blanchet ,&nbsp;Bernadette Nirmal Kumar","doi":"10.1016/j.lanepe.2025.101406","DOIUrl":"10.1016/j.lanepe.2025.101406","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"56 ","pages":"Article 101406"},"PeriodicalIF":13.0,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144721215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resistance battle fatigue in the face of ongoing protests in Israel","authors":"Michal Mahat-Shamir ,&nbsp;Ayelet Oreg ,&nbsp;Ester Zychlinski","doi":"10.1016/j.lanepe.2025.101418","DOIUrl":"10.1016/j.lanepe.2025.101418","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"56 ","pages":"Article 101418"},"PeriodicalIF":13.0,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144721216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between socioeconomic factors and semaglutide use for weight loss: a population-based cross-sectional study in Denmark","authors":"Rasmus Bo Hasselbalch ,&nbsp;Mille Kyhn Andrea ,&nbsp;Carl Villaro Nolsøe ,&nbsp;Mathias Hindborg ,&nbsp;Puriya Daniel Würtz Yazdanfard ,&nbsp;Kathrine Kold Sørensen ,&nbsp;Stig Nikolaj Fasmer Blomberg ,&nbsp;Helle Collatz Christensen ,&nbsp;Claus Graff ,&nbsp;Cæcilie Stilling Denholt ,&nbsp;Shoaib Afzal ,&nbsp;Børge G. Nordestgaard ,&nbsp;Kristian Kragholm ,&nbsp;Henning Bundgaard ,&nbsp;Kasper Karmark Iversen ,&nbsp;Christian Torp-Pedersen ,&nbsp;Mikkel Porsborg Andersen","doi":"10.1016/j.lanepe.2025.101398","DOIUrl":"10.1016/j.lanepe.2025.101398","url":null,"abstract":"<div><h3>Background</h3><div>Glucagon-like peptide-1 agonists like semaglutide are effective treatments for obesity. High costs may create economic barriers. This study examines the association between income and prescriptions for semaglutide for weight loss.</div></div><div><h3>Methods</h3><div>This nationwide register-based cross-sectional study of all adults in Denmark without diabetes, analyzed the association between household income adjusted for family size divided into quartiles and semaglutide prescription redemption for weight loss. We obtained weight and height on a representative sample of the population from The Copenhagen General Population Study which randomly selected individuals in 2014–2019. Obesity was defined as a body mass index &gt;30 kg/m².</div></div><div><h3>Findings</h3><div>A total of 4,531,146 adult individuals were included after excluding individuals with diabetes (186,823, 3·8%), and individuals without income data (146,639, 3·0%). The proportion of individuals with a redeemed semaglutide prescription increased with income, from 1·3% (n = 13,925) in the lowest income quartile to 3·6% (n = 41,298) in the highest. Conversely, in a representative sample of 36,391 individuals, the proportion living with obesity was 26% (n = 1310) in the lowest income quartile compared to 13% (n = 1872) in the highest. During the year 2023 we found a general increase in Semaglutide use from 40,605 (0·9%) in the first quarter of 2023 to 85,250 (1·9%) in the fourth quarter, which was most pronounced in women in the highest income group with an increase from 10,818 (1·9%) to 23,069 (4·1%).</div></div><div><h3>Interpretation</h3><div>Semaglutide use increased with income while obesity declined. This suggests that economic concerns lead to a systematic undertreatment for obesity for low-income individuals, potentially exacerbating existing health inequalities.</div></div><div><h3>Funding</h3><div>None.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"56 ","pages":"Article 101398"},"PeriodicalIF":13.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transformative collaborations in a time of change: Europe’s unique model for public-private-philanthropic partnerships","authors":"Carmen Hurtado del Pozo ,&nbsp;Niklas Blomberg","doi":"10.1016/j.lanepe.2025.101401","DOIUrl":"10.1016/j.lanepe.2025.101401","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"56 ","pages":"Article 101401"},"PeriodicalIF":13.6,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144703704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in epilepsy mortality of three incidence cohorts across 2006–2023 in Sweden: a matched register-based study","authors":"Johan Zelano ,&nbsp;André Idegård ,&nbsp;David Larsson","doi":"10.1016/j.lanepe.2025.101388","DOIUrl":"10.1016/j.lanepe.2025.101388","url":null,"abstract":"<div><h3>Background</h3><div>Idiopathic epilepsy alone accounts for a large health burden as shown in the Global Burden of Diseases Study. In countries with ageing populations, secondary epilepsies are now even more common. Altered clinical practice and reduced use of older enzyme-inducing drugs may be beneficial, but understanding of trends in the prognosis of all epilepsy is needed. Our objective was to determine and study trends in mortality in persons with epilepsy in Sweden through 2006–2023.</div></div><div><h3>Methods</h3><div>We performed a matched cohort study by cross-referencing National Patient, Drug, and Cause of Death Registers. We included all persons with a diagnosis of epilepsy and antiseizure medication (ASM) after 2006 (n = 61,375) and three age-/sex-matched comparators/case. Mortality was assessed for three incidence cohorts; 2006–2010, 2011–2015, and 2016–2020, totally and in four subgroups: age &gt;50, vascular disease, generalized epilepsy, and age &lt;20. Risk of death was assessed by Cox regression.</div></div><div><h3>Findings</h3><div>Carbamazepine and valproic acid were common first ASMs in 2006–2010, but replaced by levetiracetam by 2016–2020. Valproate became less common in generalized epilepsy. The adjusted hazard ratio [HR] for death was 1.99 (95% confidence interval [CI]:1.90–2.08) in 2006–2010 and 1.90 (95% CI: 1.82–1.99) in 2016–2020. The adjusted HR for death was 1.59 (95% CI: 1.50–1.68) for persons with cardiovascular disease versus comparators during 2016–2020. A sensitivity analysis showed that the excces risk of cardiovascular death had decreased between our cohorts. Young persons with epilepsy had a 30–50 fold increased HR of death. Dementia and vascular disease were important risk factors for death in persons with epilepsy.</div></div><div><h3>Interpretation</h3><div>Mortality in epilepsy has remained largely unchanged relative to age- and sex matched comparators. The increased use of non-inducing ASMs may have reduced vascular risk slightly. Efforts should be targeted to specific patient groups, particularly regarding epilepsy management in the young and vascular and neurodegenerative comorbidities in older persons with epilepsy.</div></div><div><h3>Funding</h3><div><span>Swedish Research Council</span>, Swedish State through the <span>ALF agreement</span>, <span>Knut and Ragnvi Jacobsson foundation</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"56 ","pages":"Article 101388"},"PeriodicalIF":13.6,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144685763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing oral health in the Balkans: promoting selective caries removal for underserved populations","authors":"Rasa Mladenovic","doi":"10.1016/j.lanepe.2025.101399","DOIUrl":"10.1016/j.lanepe.2025.101399","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"56 ","pages":"Article 101399"},"PeriodicalIF":13.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144679449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}